OVERVIEWArena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena. The boards of directors of both companies have unanimously approved the transaction. A press release with transaction information can be found here.
The proposed acquisition allows us to utilize Pfizer’s established infrastructure across global markets and expertise in Inflammation and Immunology, as well as Cardiology, to accelerate and advance Arena’s pipeline. We believe this transaction represents the best next step for the company and will potentially allow us to more rapidly address unmet need for a broader number of patients with inflammatory and cardiovascular diseases.
The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena stockholders. We are committed to executing a smooth transition. Between now and the closing date, operations at Arena will not change. Arena will continue to enroll studies and drive forward on our stated timelines.
Please see our Q&A on the transaction here and find out more information through the links below.
See our disclaimer on the transaction here.